30
CARDIOVASCULAR
hamburger
Assessing for Coronary Microvascular Dysfunction (CMD)

Better Treatment Starts With An Accurate Diagnosis

To discover the root cause of persistent angina, patients may need an accurate diagnosis for Coronary Microvascular Dysfunction (CMD) that requires more than the angiogram alone.1 Comprehensive physiology testing of both the epicardial arteries and microcirculation can help provide a clear diagnosis to guide treatment and improve patient outcomes.2

The Microvasculature Can Have a Major Clinical and Economic Impact

The microcirculation carries far more myocardial blood volume compared to the epicardial arteries. CMD can be defined as impaired blood flow to the microcirculation, which is largely responsible for the regulation and distribution of blood flow to the myocardium.1

INOCA is Not Benign: The Effect On Clinical Outcomes

Patients with INOCA can be diagnosed for CMD by measuring IMR and CFR.3 Patients with abnormal CFR have an increase in major adverse cardiac events (MACE) including:

  • Myocardial infarction1
  • Stroke1
  • Heart failure1,3
  • Cardiovascular death1

Additionally, these patients have an increase in diastolic dysfunction and cardiac death.4

Coronary Flow Reserve Associated with MACE Risks1

The clinical spectrum of CMD may be characterized by three factors:1

  • The severity of CMD
  • The degree of atherosclerosis
  • Any associated clinical risks

Clinical Spectrum of CMD1

The Impact On Healthcare Costs

A clear, accurate CMD diagnosis can help reduce healthcare resource consumption.5

  • For U.S. patients with INOCA symptoms, the economic cost of ineffective treatment is $13,977 per patient annually due to absenteeism (inability to go to work) and presenteeism (productivity loss at work).6
  • An economic analysis of the CorMicA study showed that a comprehensive physiology assessment is cost-effective compared to standard care (medical therapy and cardiac rehabilitation care) at 1-year follow-up.7
  • In fact, an accurate CMD diagnosis can help reduce healthcare resource consumption,8 resulting in lower costs for hospitals and patients9 with a savings from $2,100 (Netherlands) to $7,300 (U.S.) per hospitalization avoided (2017 costs).10

INOCA Patient Identification

40-60% of all elective patients undergoing angiography suffer from INOCA. Up to half of this patient population might have angina due to CMD.11,12

  • Angina post-PCI occurs in 20-30% of patients at 1-year and may be caused by CMD.13
  • CMD predominantly affects women, having been detected in up to 50% of women presenting with chest pain. A definitive diagnosis is critical as women with this condition are at an increased risk of cardiovascular events in the future.14,15
     

Symptoms of CMD can include:16

  • Discomfort in the left arm, jaw, neck, back or abdomen associated with chest pain
  • Shortness of breath
  • Tiredness and lack of energy

Assessing Patients

Guide to Identifying CMD Patients

Understanding the symptoms may help you determine if your patient could benefit from comprehensive physiology testing. Patients suffering from CMD may include:8

  • Patients suffering from angina whose coronary arteries appear clear under angiography
  • Patients suffering from angina post-PCI
  • Patients with a negative stress test but suffering from angina
  • Patients presenting to the ER with chronic angina
  • Female patients suffering from angina

Other symptoms may include chest pain, shortness of breath, and more.

Download our guide to identifying CMD patients

INOCA International Symptom Tracker

To help patients better monitor their INOCA symptoms, triggers and determine optimal next steps, you can share the Symptom Tracker developed by INOCA International

Helping Patients

The CorMicA (Coronary Microvascular Angina) study revealed that patients may benefit when CMD is accurately diagnosed and appropriately treated. 27% of patients saw improvement in angina severity at 1 year with optimized medical therapy.17
 

Sustained Angina Improvement with CMD Treatment17,†

PressureWire™ X Guidewire with the CoroFlow Cardiovascular System is the only* solution for the catherization laboratory able to assess both the epicardial arteries and the microvasculature that can give patients the accurate diagnosis that they deserve.17,18,19

Connect with your partnering referring physician to discuss how your access to the PressureWire™ X Guidewire and CoroFlow Cardiovascular System can benefit their patients with angina and no angiographic abnormalities.

Learn more about PressureWire™ X Guidewire and CoroFlow Cardiovascular System.

Explore educational resources

Assess both the epicardial arteries and microvasculature

*With Index of Microcirculatory Resistance (IMR), Coronary Flow Reserve (CFR), Fractional Flow Reserve (FFR) and Resting Full-Cycle Ratio (RFR).
†According to the Seattle Angina Questionaire score.
 

References

  1. Taqueti, VR. et al. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:2625–2641.
  2. Lee, B. et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015;131;10540-1060
  3. Gulati, MI., et al. 2021 AHA/ALL Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation 2021;1440368-454.
  4. Knuuti, J., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal 2020:41,407-477.
  5. Lee, B., et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015:131:1054-1060.
  6. Schumann, CL., et al. Functional and economic impact of INOCA and influence of coronary microvascular dysfunction. JACC Cardiovascular Imaging 2021; 14: 1369-79.
  7. Heggie, R., et al. A cost-effectiveness analysis of the BHF CorMicA Trial. Interventional Journal of Cardiology 2021.
  8. Kunadian, V., et al. EAPCI Expert Consensus. Eur Heart J 2020;0:1-21.
  9. Reriani, M., et al. Coronary endothelial function testing may improve long-term quality of life in subjects with microvascular coronary endothelial dysfunction. Open Heart. 2019 6:8000870.
  10. Omerovic, E., et al. FFR-Guided Complete Revascularization During Primary Angioplasty: Effects on Societal Costs. EuroPCR 2017.
  11. Patel, M., et al. (2010). Low diagnostic yield of elective coronary angiography. The New England Journal of Medicine. 2010; 363;498.
  12. Maas, A. et al. Microvascular angina: diagnosis, assessment, and treatment. EMJ Int Cardiol. 2019; 7[Suppl 1]2-17.
  13. Jeremias, et al. DEFINE PCI. TCI 2019.
  14. Kuruvilla, S., & Kramer, C. MI. (2013). Coronary microvascular dysfunction in women: an overview of diagnostic strategies. Expert review of cardiovascular therapy, 11(11), 1515-1525.
  15. Garcia, M., et al. (2016). Cardiovascular Disease in Women: Clinical Perspectives. Circulation Research, 118(8), 1273-1293.
  16. Mayo Clinic webpage: Small vessel disease accessed on June 2022 at  https://www.mayoclinic.org/diseases-conditions/small-vessel-disease/symptoms-causes/syc-20352117.
  17. Ford, TJ. et al. 1-year outcomes of angina management guided by invasive coronary function testing (CorMicA). JACC Intv. 2020;13:33-45.
  18. PressureWire™ X Guidewire Instructions for Use (IFU). Coroflow‡ Cardiovascular System (IFU). Refer to IFUs for additional information.
  19. Pijls, NH, et al. Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients with Multivessel Coronary Artery Disease. 2-Year Follow-Up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) Study. JACC. 2010; 56(3): 177-184.
Request Abbott Sales Rep

MAT-2206706 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.